ALUMIS INC. — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
Alumis' Phase 2b LUMUS trial (408 patients, 48 weeks) of envudeucitinib for systemic lupus erythematosus failed primary and secondary endpoints in the overall population. However, a prespecified subgroup of 127 IFNGS-high patients showed robust efficacy: BICLA response 52.6% (40mg BID) vs. 28.6% placebo (p=0.374 overall; ~+24pp in subgroup); SRI-4 60.9% vs. 33.1% (p=0.028 overall; ~+28pp in subgroup). Safety profile was favorable with no new signals. Alumis plans End-of-Phase 2 meetings with FDA/EMA to discuss Phase 3 design for the IFNGS-high population and remains on track to file an NDA for envudeucitinib in plaque psoriasis in Q4 2026.
Why this rating
Trial failure in overall SLE population is negative, but strong IFNGS-high subgroup efficacy and biomarker-guided path forward is moderately positive. Psoriasis NDA filing on track. For $183M market-cap biotech, this is material but not trajectory-altering—outcome depends heavily on Phase 3 success and regulatory acceptance of biomarker strategy.
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.